Impact of cancer diagnosis on distribution and trends of cardiovascular hospitalizations in the USA between 2004 and 2017.
Cardio- oncology
prognosis
trends
Journal
European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796
Informations de publication
Date de publication:
26 10 2022
26 10 2022
Historique:
received:
20
06
2022
revised:
25
07
2022
accepted:
28
07
2022
pubmed:
2
8
2022
medline:
29
10
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
There is limited data on temporal trends of cardiovascular hospitalizations and outcomes amongst cancer patients. We describe the distribution, trends of admissions, and in-hospital mortality associated with key cardiovascular diseases among cancer patients in the USA between 2004 and 2017. Using the Nationwide Inpatient Sample we, identified admissions with five cardiovascular diseases of interest: acute myocardial infarction (AMI), pulmonary embolism (PE), ischaemic stroke, heart failure, atrial fibrillation (AF) or atrial flutter, and intracranial haemorrhage. Patients were stratified by cancer status and type. We estimated crude annual rates of hospitalizations and annual in-hospital all-cause mortality rates. From >42.5 million hospitalizations with a primary cardiovascular diagnosis, 1.9 million (4.5%) had a concurrent record of cancer. Between 2004 and 2017, cardiovascular admission rates increased by 23.2% in patients with cancer, whilst decreasing by 10.9% in patients without cancer. The admission rate increased among cancer patients across all admission causes and cancer types except prostate cancer. Patients with haematological (9.7-13.5), lung (7.4-8.9), and GI cancer (4.6-6.3) had the highest crude rates of cardiovascular hospitalizations per 100 000 US population. Heart failure was the most common reason for cardiovascular admission in patients across all cancer types, except GI cancer (crude admission rates of 13.6-16.6 per 100 000 US population for patients with cancer). In contrast to declining trends in patients without cancer, primary cardiovascular admissions in patients with cancer is increasing. The highest admission rates are in patients with haematological cancer, and the most common cause of admission is heart failure.
Sections du résumé
BACKGROUND AND AIMS
There is limited data on temporal trends of cardiovascular hospitalizations and outcomes amongst cancer patients. We describe the distribution, trends of admissions, and in-hospital mortality associated with key cardiovascular diseases among cancer patients in the USA between 2004 and 2017.
METHODS
Using the Nationwide Inpatient Sample we, identified admissions with five cardiovascular diseases of interest: acute myocardial infarction (AMI), pulmonary embolism (PE), ischaemic stroke, heart failure, atrial fibrillation (AF) or atrial flutter, and intracranial haemorrhage. Patients were stratified by cancer status and type. We estimated crude annual rates of hospitalizations and annual in-hospital all-cause mortality rates.
RESULTS
From >42.5 million hospitalizations with a primary cardiovascular diagnosis, 1.9 million (4.5%) had a concurrent record of cancer. Between 2004 and 2017, cardiovascular admission rates increased by 23.2% in patients with cancer, whilst decreasing by 10.9% in patients without cancer. The admission rate increased among cancer patients across all admission causes and cancer types except prostate cancer. Patients with haematological (9.7-13.5), lung (7.4-8.9), and GI cancer (4.6-6.3) had the highest crude rates of cardiovascular hospitalizations per 100 000 US population. Heart failure was the most common reason for cardiovascular admission in patients across all cancer types, except GI cancer (crude admission rates of 13.6-16.6 per 100 000 US population for patients with cancer).
CONCLUSIONS
In contrast to declining trends in patients without cancer, primary cardiovascular admissions in patients with cancer is increasing. The highest admission rates are in patients with haematological cancer, and the most common cause of admission is heart failure.
Identifiants
pubmed: 35913736
pii: 6652898
doi: 10.1093/ehjqcco/qcac045
pmc: PMC9603542
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
787-797Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/17/81/33 318
Pays : United Kingdom
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Eur Heart J. 2022 Feb 22;43(8):716-799
pubmed: 35016208
Heart Fail Clin. 2015 Oct;11(4):515-22
pubmed: 26462091
Oncotarget. 2017 Jun 27;8(37):61837-61845
pubmed: 28977908
Semin Oncol. 2006 Jun;33(3 Suppl 8):S22-7
pubmed: 16781286
BMJ Open. 2019 May 30;9(5):e022664
pubmed: 31152022
Rep Pract Oncol Radiother. 2020 Jan-Feb;25(1):13-19
pubmed: 31762693
Eur Heart J Qual Care Clin Outcomes. 2022 Apr 18;:
pubmed: 35435219
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Breast Cancer Res Treat. 2022 Jun;193(3):669-675
pubmed: 35429322
Int J Cardiol. 2022 Sep 15;363:210-217
pubmed: 35752208
Int J Cardiol. 2021 Oct 15;341:76-83
pubmed: 34333019
JACC CardioOncol. 2022 Mar 15;4(1):113-123
pubmed: 35492818
Med Sci (Basel). 2021 Jan 30;9(1):
pubmed: 33573146
Blood Rev. 2016 May;30(3):169-78
pubmed: 26578029
J Am Heart Assoc. 2017 Sep 22;6(9):
pubmed: 28939718
J Card Fail. 2019 Jul;25(7):516-521
pubmed: 30769035
Circ Res. 2017 Apr 28;120(9):1501-1517
pubmed: 28450367
J Am Coll Cardiol. 2013 Jun 11;61(23):2319-28
pubmed: 23583253
Blood. 2007 Mar 1;109(5):1878-86
pubmed: 17119114
Heart Fail Rev. 2019 Nov;24(6):989-995
pubmed: 31175492
Cancer Chemother Pharmacol. 2019 Sep;84(3):599-607
pubmed: 31203389
Am J Cardiol. 2005 Jun 15;95(12):1525-6
pubmed: 15950590
PLoS One. 2021 Mar 3;16(3):e0246813
pubmed: 33657143
J Gen Intern Med. 2021 Aug;36(8):2517-2518
pubmed: 32705476
Ann Oncol. 2010 Sep;21(9):1825-1833
pubmed: 20211871
Int J Clin Pract. 2021 Nov;75(11):e14841
pubmed: 34514707
Thromb Haemost. 2017 Jan 5;117(1):57-65
pubmed: 27709226
Circ Heart Fail. 2013 May;6(3):606-19
pubmed: 23616602
Curr Atheroscler Rep. 2012 Aug;14(4):373-81
pubmed: 22528522
Lancet. 2019 Sep 21;394(10203):1041-1054
pubmed: 31443926
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
Ann Oncol. 2009 May;20(5):816-27
pubmed: 19153118
J Clin Oncol. 2007 Sep 1;25(25):3808-15
pubmed: 17664460